Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
of the U-M Medical School in 1850. Michigan Medicine is comprised of over 26,000 employees and our vision is to attract, inspire, and develop outstanding people in medicine, sciences, and healthcare
-
Apply Now Job Summary The Nucleic Acid Therapeutics Core is a newly initiated program at the University of Michigan to design and synthesize nucleic acid therapeutic molecules for early-stage
-
the site of many groundbreaking medical and technological advancements since the opening of the U-M Medical School in 1850. Michigan Medicine is comprised of over 30,000 employees and our vision is to
-
to? Excellent medical, dental and vision coverage effective on your very first day 2:1 Match on retirement savings Generous PTO program State of the Art technology Complimentary access to continuing education (CE
-
Benefits can you Look Forward to? Excellent medical, dental and vision coverage effective on your very first day 2:1 Match on retirement savings Generous PTO program State of the Art technology Complimentary
-
victor for the greater good. What Benefits can you Look Forward to? Excellent medical, dental and vision coverage effective on your very first day 2:1 Match on retirement savings Generous PTO program State
-
and vision coverage effective on your very first day 2:1 Match on retirement savings Generous PTO program State of the Art technology Complimentary access to continuing education (CE) credits via
-
leading multiple research initiatives that leverage imaging and computational methods to address critical challenges in urology. Ongoing efforts include the development of dynamic contrast-enhanced
-
Apply Now Job Summary Working with the Faculty Director, Managing Director, Program Manager, and a team of student interns, this role will contribute to the creation and execution of a suite of
-
Apply Now Job Summary The Nucleic Acid Therapeutics Core is a newly initiated program at the University of Michigan to design and synthesize nucleic acid therapeutic molecules for early-stage